Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 5/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31104582 | 0.79 | AOC3 (0.53) | AOC3KDM4ECYP2C19JAK3ACACB | |
| SCHEMBL20148202 | 0.76 | GAA (0.33) | POLB | |
| SCHEMBL19864978 | 0.74 | SMO (0.43) | AOC3KDM4ECYP2C19POLB | |
| SCHEMBL28539492 | 0.74 | HRH3 (0.40) | AOC3KDM4ECYP2C19SCDPOLB | |
| SCHEMBL20148207 | 0.73 | AOC3 (0.40) | AOC3HCRTR2ACACB | |
| SCHEMBL28390577 | 0.72 | KDM4E (0.40) | AOC3KDM4ECYP2C19ACACBDEGS1 | |
| SCHEMBL28385258 | 0.72 | AOC3 (0.42) | AOC3KDM4EHCRTR2 | |
| SCHEMBL28643581 | 0.71 | AOC3 (0.42) | AOC3KDM4ECYP2C19ACACB | |
| SCHEMBL28660607 | 0.71 | AOC3 (0.42) | AOC3KDM4ECYP2C19ACACB | |
| SCHEMBL15952948 | 0.69 | ALDH1A1 (0.44) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134688-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134688-A1 | NOVEL COMPOUNDS | RIPK2, RIPK1, RIPK4 | AOC3 4660/4885KDM4E 2958/4885CYP2C19 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.